checkAd
    Startseite > Aktien > Coya Therapeutics > Nachrichten
    Coya Therapeutics Aktie
    8,6000
     
    USD
    +2,02 %
    +0,1700 USD
    Letzter Kurs 27.04.24 Nasdaq
    8,4200
     
    USD
    700 STK
    Geldkurs 26.04.24
    8,6000
     
    USD
    300 STK
    Briefkurs 26.04.24
    ISIN: US22407B1089 · WKN: A3DZRY · SYM: COYA · USA

    Neueste Nachrichten

    Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
    26.04.24 · Business Wire (engl.) · Coya Therapeutics
    Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
    22.04.24 · Business Wire (engl.) · Coya Therapeutics
    Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
    18.04.24 · Business Wire (engl.) · Coya Therapeutics
    Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
    08.04.24 · Business Wire (engl.) · Coya Therapeutics
    Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
    19.03.24 · Business Wire (engl.) · Coya Therapeutics
    Coya Therapeutics to Participate in BTIG Fireside Discussion
    12.03.24 · Business Wire (engl.) · Coya Therapeutics
    Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
    12.03.24 · Business Wire (engl.) · Coya Therapeutics
    Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
    06.03.24 · Business Wire (engl.) · Coya Therapeutics
    Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
    29.02.24 · Business Wire (engl.) · Coya Therapeutics
    Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
    22.02.24 · Business Wire (engl.) · Coya Therapeutics
    Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”
    21.02.24 · Business Wire (engl.) · Coya Therapeutics
    Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
    13.02.24 · Business Wire (engl.) · Coya Therapeutics